Business Of Biotech
by Ben Comer
Is this your podcast?Ben Comer is an independent podcast creator known for his expertise in the biopharma industry, particularly in guiding emerging biotech firms through complex challenges. His insights stem from a deep understanding of the intersection betwee…
Insights from recent episode analysis
Audience Interest
- biopharma industry insights
- organizational challenges
Podcast Focus
- biopharma leadership
- best practices sharing
Publishing Consistency
- 302 episodes total
- active for six years
Platform Reach
- available on major platforms
- no specific platforms listed
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 24 chart positions in 24 markets.
By chart position
- 🇨🇦CA · Management#49100K to 300K
- 🇺🇸US · Management#6630K to 100K
- 🇬🇧GB · Management#1985K to 30K
- 🇪🇸ES · Management#4300K to 800K
- 🇰🇷KR · Management#4930K to 100K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
259K to 762K🎙 ~2x weekly·302 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
517K to 1.5M🇪🇸52%🇨🇦20%🇺🇸7%+21 more - Active Followers
Loyal subscribers who consistently listen
207K to 610K4.1K real followers tracked across platforms
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 16 epsHosts
Recent guests
Recent episodes
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
Jun 22, 2026
55m 13s
Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Jun 15, 2026
55m 18s
The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
Jun 8, 2026
1h 24m 17s
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
Jun 1, 2026
49m 52s
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
May 25, 2026
55m 23s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/22/26 | Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocas... | 55m 13s | ||||||
| 6/15/26 | Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D. | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers. William also describes the evolution in medical affairs, why standards and... | 55m 18s | ||||||
| 6/8/26 | The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry✨ | life sciences industryAI manufacturing+3 | — | Bioprocess OnlineLife Science Connect+1 | 2026 | life sciencesAI+3 | — | 1h 24m 17s | |
| 6/1/26 | Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.✨ | CNS Drug DevelopmentNeuroscience+3 | Jeff Jonas, M.D. | Tortugas Neuroscience | — | CNSDrug Development+5 | — | 49m 52s | |
| 5/25/26 | Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane✨ | rare diseasedrug commercialization+3 | Neil McFarlane | Niemann-Pick disease type CZevra Therapeutics | — | rare diseasedrug commercialization+5 | — | 55m 23s | |
| 5/18/26 | Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.✨ | manufacturingpersonalized therapies+5 | Marinna Madrid, Ph.D. | Cellino | — | personalized medicinecell therapy+5 | — | 50m 55s | |
| 5/11/26 | Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.✨ | antibody discoverysingle-cell biology+3 | Wyatt McDonnell, Ph.D. | InfinimmuneMerck | — | antibody drugsInfinimmune+3 | — | 54m 12s | |
| 5/4/26 | From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.✨ | antisense oligonucleotidesRNA-targeting medicines+3 | Brett Monia, Ph.D. | Ionis Pharmaceuticals | — | ASO therapiesIonis Pharmaceuticals+5 | — | 55m 56s | |
| 4/27/26 | Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary✨ | CEO strategyneuroreparative peptide+3 | Adam Rogers, M.D.Rich Macary | NVG-291NervGen+2 | — | NervGenNVG-291+5 | — | 47m 37s | |
| 4/20/26 | The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw✨ | FDA decision-makingclinical trial strategy+3 | Allan Shaw | FDA | — | FDAbiotech+5 | — | 46m 53s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/13/26 | Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.✨ | biosimilarsFDA regulations+3 | Sarfaraz Niazi, Ph.D. | FDABiologics Price Competition and Innovations Act | — | biosimilarsFDA+5 | — | 58m 33s | |
| 4/6/26 | Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor✨ | radiotherapeuticsneuroendocrine tumors+3 | Thijs Spoor | Pb 212radiopharmaceuticals+1 | — | radiotherapeuticsneuroendocrine tumors+3 | — | 40m 26s | |
| 3/30/26 | Investing In Early-Stage Oncology With Yosemite's Dan McHugh✨ | oncologyinvestment+3 | Dan McHugh | Yosemite | — | oncologyinvestment+5 | — | 55m 41s | |
| 3/23/26 | Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash✨ | CAR T therapybiotech commercialization+3 | Alan Bash | CarvyktiLegend Biotech+3 | — | CAR T therapyCarvykti+5 | — | 50m 57s | |
| 3/16/26 | Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.✨ | radiotherapeuticsCNS cancers+4 | Marc Hedrick, M.D. | ReyobiqPlus Therapeutics+2 | — | radiotherapeuticsCNS cancers+5 | — | 54m 00s | |
| 3/9/26 | Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.✨ | cancer drug developmentcapital efficiency+3 | Rahul Aras, Ph.D. | Iterion Therapeutics | — | cancerdrug development+4 | — | 48m 30s | |
| 3/2/26 | Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.✨ | biologicsoral drugs+3 | Thomas von Erlach, Ph.D.Thomas von Erlach | VivtexNovo Nordisk | MIT | biologicsoral availability+7 | — | 53m 57s | |
| 2/23/26 | An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.✨ | leadershipculture+3 | Monika Sumra, Ph.D. | Bunka, Inc. | — | leadershipculture+5 | — | 58m 19s | |
| 2/16/26 | Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept ... | 56m 56s | ||||||
| 2/9/26 | Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Ar... | 42m 36s | ||||||
| 2/2/26 | BoB@JPM: Brian Hilberdink, Boehringer Ingelheim | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and ... | 44m 35s | ||||||
| 1/26/26 | BoB@JPM: Ron Cooper, enGene | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of ke... | 55m 57s | ||||||
| 1/19/26 | BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics | We love to hear from our listeners. Send us a message. The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian ta... | 36m 08s | ||||||
| 1/12/26 | A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learn... | 58m 44s | ||||||
| 1/5/26 | Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead | We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry tre... | 1h 21m 12s | ||||||
Showing 25 of 312
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Similar Audience Demographics
Podcasts that attract a similar listener profile
BioCentury This Week
BioCentury
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
The Readout Loud
STAT
The Long Run with Luke Timmerman
Timmerman Report
Biotech 2050 Podcast
Biotech 2050
Raising Health
Andreessen Horowitz, a16z Bio + Health
Conversations with Tyler
Mercatus Center at George Mason University
Chart Positions
25 placements across 24 markets.
Chart Positions
25 placements across 24 markets.